India’s domestic pharmaceutical market turnover reached Rs 1.4 lakh crore (US$ 20.03 billion) in 2019, growing 9.8 per cent year-on-year (in Rs) from Rs 129,015 crore (US$ 18.12 billion) in 2018.Indian medicines expenditure is projected to increase by 9%-12% over the next five years, making India one of the top 10 medical expenditure countries. India is the world's largest supplier of generic medicinal products, representing 20% of global drug exports generic in India (in terms of volumes). Indian drugs are exported worldwide to more than 200 countries, with the United States as the major market. Indian pharmaceutical companies capitalise in regulated and semi-regulated export opportunities.  Pharmaceutical exports from India, including bulk, intermediate, medicinal products, biology, ayush & herbal products and surgical products, reached US$ 19.14 billion in FY19, and US$ 13.7 billion in FY20 (up to Jan 2020).This article aims to discuss the working capital management of prominent pharma companies of India.

Keywords: Working Capital Management, Pharmaceutical Company, Current Assets, Current Liabilities, Business Operational Efficiency.